At his first Disciplinary Committee hearing in January 2018, the Committee directed that Dr Gerhard Schulze Allen’s name be removed from the Register after finding him guilty of serious professional misconduct in respect of four charges against him. These related to an incident of petty theft in California in the United States, and his subsequent dishonesty in not disclosing this to the College.
Following the Disciplinary Committee hearing, Dr Schulze Allen submitted an appeal to the Privy Council. In July 2019, the Privy Council partially upheld his appeal, determining that the RCVS had not proven beyond all reasonable doubt that Dr Schulze Allen’s infraction for petty theft was a conviction under Californian law and therefore Dr Schulze Allen had not made false representations to the College when he said he did not have any criminal convictions or a criminal record.
However, the Privy Council partially upheld the College’s charge that Dr Schulze Allen was dishonest and made false representations when he had, in a written application for restoration to the Register, represented that he did not have any adverse findings and that he should have declared his infraction for petty theft. The Privy Council also set aside the Disciplinary Committee’s original sanction and remitted the task of sanction back to the Disciplinary Committee.
As a result of the Privy Council’s decision, the Disciplinary Committee held a further hearing in relation to Dr Schulze Allen to decide the sanction in relation to the upheld charge against him.
The Committee noted that the aggravating factors were the fact that Dr Schulze Allen was dishonest to his regulator and in making a false declaration, demonstrated a wilful disregard for the regulatory role of the RCVS. In mitigation the Committee considered that there was no harm to animals, that it was a single and isolated incident in an otherwise unblemished career, and that he had accepted his wrongdoing, albeit at a late stage, and was developing some insight.
The Committee considered whether a reprimand or warning would be the most appropriate sanction but determined that this would not reflect the seriousness of the dishonesty in this case, nor maintain public confidence in the profession or uphold proper professional standards of conduct and behaviour.
Ian Green, chairing the Committee and speaking on its behalf, said: "The Committee concluded that the appropriate and proportionate sanction is suspension from the Register for a period of three months. A period of three months reflects the seriousness of the charge. Such a sanction sends a clear message to Dr Schulze Allen, the profession and the public that behaving dishonestly towards the regulator is a serious matter. The Committee considered that removal from the Register would be disproportionate given that this is a single incident and Dr Schulze Allen now accepts his wrongdoing."
Equip Artervac is indicated for the active immunisation for horses against equine arteritis virus to reduce the clinical signs and shedding of virus in nasal secretions following infection.
Zoetis says it is working hard to resolve the situation and apologises for any convenience caused.
For more information, contact your Zoetis Account Manager or the Zoetis Technical Team on customersupportUK@zoetis.com or 0845 300 9084 choosing option 1.
Miss Johnson was convicted at North Somerset Magistrates’ Court following a guilty plea of the offence of theft by employee in December 2023, after she stole buprenorphine belonging to Yatton Vets earlier that year.
She was sentenced to a fine of £120, a surcharge of £48, and costs of £85.
There were four further charges against Miss Johnson.
Charge one related to Miss Johnson stealing 5ml of methadone in December 2022 from her employer, Vets4Pets in Bristol, and injecting herself with the methadone.
The police investigated the incident and Miss Johnson accepted a conditional caution for the theft, the condition being she should attend a drug awareness course.
Charge two related to Miss Johnson dishonestly taking a syringe of methadone in August 2023 from her employer, the Langford Small Animal Hospital, and injecting herself with it.
Charge three related to two dates in September 2023 when she dishonestly took methadone, gabapentin and buprenorphine from Yatton Vets, her then employer, injecting herself with the buprenorphine and then working when unfit to do so.
Miss Johnson was later convicted of theft in relation to the buprenorphine (charge five).
Charge four related to an incident in November 2023, when Miss Johnson dishonestly took a syringe of buprenorphine from Bristol PDSA, for the purposes of self-administration, and was dishonest both to other members of staff and in the clinical records about the circumstances of taking the buprenorphine.
Charge five was in relation to Miss Johnson’s criminal conviction.
At the outset of the hearing, Miss Johnson admitted all charges in their entirety.
Having reviewed all the evidence and taken Miss Johnson’s admissions into account, the Committee found each of the charges proved.
After the criminal proceedings had finished and had been reported to the College, Miss Johnson wrote a letter expressing her deepest apologies to both the RCVS and the profession.
Within this she also made it clear that she took full responsibility for her actions.
In a later statement, she added that she had tried to use the experience to learn and improve in every aspect of her career and life and did not want to defend her behaviour.
Within this statement she also retracted a previous request to resign from the register, stating that she would accept any outcome to the investigation.
In deciding whether the proved charges amounted to serious professional misconduct, the Committee took the following aggravating factors into account:
The Committee identified no mitigating factors and concluded that for each of the individual charges Miss Johnson’s conduct fell far short of the conduct expected of a member of the profession and that each of the charges one to four amounted to serious professional misconduct.
In relation to charge five, the criminal conviction, the Committee noted that the nature and the circumstances of the offence involved dishonesty, abuse of her professional position regarding access to controlled drugs, breach of her employer’s trust, and that the misconduct took place notwithstanding an investigation by the police for similar conduct in December 2022.
The Committee therefore concluded that charge five rendered Miss Johnson unfit to practise.
When deciding on a sanction, the Committee took into account mitigating factors, which included:
The Committee found no further aggravating factors at this stage.
Kathryn Peaty, chairing the Committee and speaking on its behalf said: “The Committee considered that the overall misconduct proved so serious and was incompatible with remaining on the register.”
She added: “The Committee accepted that Miss Johnson was currently likely to be drug-free on the basis of her evidence and that of her referee, but it noted that independent testing proving she had been drug free for any period of time was not available to it.
"Furthermore, Miss Johnson had been unable to demonstrate that she had worked without any incident recently as she had accepted she had been dismissed from her recent job.
“Having taken into account all of the aggravating and mitigating factors, and balancing the public interest and the need to uphold and maintain standards within the profession, and having decided that Miss Johnson’s insight was limited, the Committee concluded that the sanction of ‘removal’ was the only proportionate sanction it could impose in this case.
"It also decided that such a sanction maintained public confidence in the veterinary profession, safeguarded animal welfare and protected the public from any future risk of repetition of similar behaviour.
“The Committee therefore directed that the Registrar remove Miss Johnson’s name from the register of veterinary nurses forthwith.”
Virbac has announced the launch of Carprox Vet, a carprofen-based NSAID indicated for the alleviation of post-operative pain and inflammation following orthopaedic and soft tissue surgery in dogs and cats and for the treatment of chronic pain and inflammation in dogs.
Carprox is presented as a palatable tablet for dogs in three sizes - 20 mg, 50 mg and 100 mg. An injectable 50 mg/ml solution for dogs and cats has also been launched (in bottles of 20ml).
Virbac Marketing Manager for Companion Animals Simon Boulton MRCVS said: "We launched our meloxicam-based solution for acute and chronic pain, Inflacam, in 2013. With the arrival of Carprox Vet, we are now able to offer vets a carprofen-based alternative for added flexibility and choice. We are delighted to add it to our product range and are proud to say that Virbac now offers one of the widest ranges of products for the treatment of small animals in the UK."
Petplan Equine, the equine insurance provider, has announced the three finalists for the inaugural Petplan Equine Vet of the Year Award.
They are:
The winner of this new people's award will be announced at the glittering 20th annual Animal Health Trust (AHT) Equestrian Awards ceremony to be held at London's Royal Lancaster Hotel on the evening of Thursday 6th November 2008.
Owners and riders were asked nominate their local equine vet for the award if they felt that they were deserving of the recognition that this accolade would bring. A short list was drawn up from the nominations received and an independent panel has selected the finalists from whom the winner will be announced and receive his or her award at the AHT Equestrian Awards.
This year marks the 20th anniversary of the Animal Health Trust Equestrian Awards, which recognise the outstanding achievements made by horses, riders, owners and trainers throughout the equestrian world. This milestone coincides with Petplan Equine's 20th anniversary and, since 1994 when the Petplan Equine Charitable Trust was founded, it has raised over £5 million, almost £500,000 of which has been donated to the AHT to fund research and development.
Jo Whittaker of Petplan Equine said: "It has been a privilege to be involved with the AHT Awards over the years. We are particularly excited to be able to recognise the amazing hard work and commitment of people within the equine veterinary profession and those who provide outstanding service to horse owners. We received some very strong nominations and selecting just three was not easy although, in the case of the finalists it was clear that each consistently went beyond the call of duty."
She added: "Horse welfare is paramount at Petplan Equine and the company is committed to promoting responsible horse ownership, through its charitable contributions, wide range of policies and publications such as the Horse Handbook. This award has been created to give the equine community the opportunity to acknowledge and celebrate the vet who has made the most outstanding contribution to the care of horses."
The winner will be posted on www.petplanequine.co.uk on Friday 7th November
To be entered into the prize draw, you need to view three short webinars on feline chronic kidney disease (CKD) on the Boehringer Academy website – www.boehringer-academy.co.uk.
The online seminars, which each last for approximately 20-30 minutes, count towards CPD and are as follows:
Tuesday 20 June at 7.30pmThe role of IDEXX SDMA in early diagnosis of feline CKDLearn how you can detect feline CKD earlier and more reliably with the IDEXX SDMA blood testSusan Randell, Head of Internal Medicine at IDEXX Laboratories
Tuesday 4 July at 7.30pmThe importance of early diagnosis in feline CKDUnderstand the importance of early diagnosis in cases of CKD and the impact this can have on progression of the diseaseSarah Caney, RCVS Recognised Specialist in Feline Medicine
Tuesday 18 July at 7.30pmThe balanced approach to feline CKDDiscover more about the balanced approach to managing the progression of feline CKDSarah Caney, RCVS Recognised Specialist in Feline Medicine
The three-day ISFM congress takes place at Le Méridien Phuket Beach Resort from 7-9 November. The congress will explore the latest developments in feline medicine and keynote speakers, Carolyn O’Brien and Jessica Quimby, will cover a range of current and challenging feline medicine topics. Local speakers complement the varied programme, which aims to offer practical hints and tips for delegates to take back and use in clinic.
The prize includes flights, transfers and bed and breakfast accommodation for two people for three nights in Phuket, as well as two delegate tickets to the ISFM congress. The prize draw will take place w/c 14 August.
To enter, watch all three new Semintra webinars on the Boehringer Academy website: www.boehringer-academy.co.uk.
The double-blind placebo-controlled study will examine whether the pheromone collar can help reduce the severity or development of certain potentially problematic behaviours in puppies and it is open to puppies less than 12 weeks of age.
Puppies will have to wear a collar until they are six months of age and their owners will be asked to complete a check sheet relating to their puppy’s behaviour every month. Each month a new collar will be sent direct to their home.
To encourage enrolment, the University of Lincoln is offering veterinary professionals a £10 voucher for every successful sign up to the trial.
Owners who complete all questionnaires will receive a pack of canine health and welfare goodies from Ceva Animal Health. The pack will include Adaptil Junior, Adaptil Transport and Logic Oral Hygiene Gel.
Owners will also be entered into a draw to win an iPad.
A marketing pack is available to raise awareness of the study and includes a waiting room poster, owner leaflets and a social media post for Twitter, Facebook or Instagram.
For further information, email the University of Lincoln at puppydevelopment@lincoln.ac.uk.
David Chalkley MRCVS faces four alleged charges:
At the start of the hearing Mr Chalkley made no admissions as to the charges but he had made an application for an adjournment based on undertakings to remove himself from the Register and never to apply to be restored to the Register.
In addressing the Committee on behalf of Mr Chalkley, his counsel said that Mr Chalkley denied all charges of dishonesty, that there was no evidence of harm to animals as a result of the alleged conduct, that there had been no complaint from the client and that he had repaid all the sums he had received for tuberculin testing on the farm in question.
His counsel also submitted that a full hearing would be expensive and time-consuming, and that it would serve no useful purpose as animal welfare and the protection of the public would be served by Mr Chalkley’s proposed undertakings.
Counsel on behalf of the RCVS confirmed that the College did not oppose the application and confirmed that the Animal Plant and Health Agency did not object.
However, the Disciplinary Committee concluded that because the case concerned issues of alleged dishonesty in veterinary certification over a prolonged period of time and the importance of public trust in the accuracy and reliability of that process, there was a need to hold a full, public hearing into Mr Chalkley’s alleged conduct.
Ian Arundale, chairing the Committee and speaking on its behalf, said: “The Committee expressed no view as to whether the allegations could be substantiated or not and it recognised that the process of determining the allegations would be burdensome for many, particularly the respondent.
"It was satisfied, however, that a reasonable and fully informed member of the public would be disturbed to learn that allegations of this kind had not been the subject of a formal determination by the Disciplinary Committee. The respondent’s own interests had to take second place to this important public interest.
“The Committee therefore declined to accept the application to adjourn this inquiry [until an unspecified date] and directed that arrangements should now be considered for the listing of a hearing in this case.”
It is expected that the full hearing will take place in spring 2021.
Eurovet Animal Health has launched a new product, Bovocycline 2000 mg pessary for cattle.
Bovocycline 2000 is the only veterinary licenced antibiotic pessary for the treatment of retained foetal membranes in cattle. It is licenced for the treatment of post parturient disorders in cattle, for administration after dystocia, retained foetal membranes (RFMs) and endometritis.
According to Eurovet, the incidence of retained foetal membranes in cows varies from zero to 25 per cent, but the average is around 4 per cent in most herds. RFMs result in reduced cow fertility and a higher risk of culling due to poor fertility. Pessaries are still considered the preferred treatment for vulval discharges in cattle by farmers.
Ruth Vernon, Technical Services Manager for Eurovet said: "The control of post partum problems in cattle is rarely straight forward, but it is great to have a veterinary licensed treatment designed specifically for this purpose, in one pessary that contains 2000mgs tetracycline".
For more information please contact Eurovet Animal Health. Tel: 01223 257933. E-mail: office@eurovet-ah.co.uk www.eurovet-ah.co.uk
Firstly, the BVA recommends that more work needs to be done in order to clarify and communicate the duties that can already be delegated to Registered Veterinary Nurses under Schedule 3.
In addition, the Association says that:
there should be an expanded role for RVNs in general anaesthesia, where the veterinary surgeon maintains overall responsibility
consideration should be given to granting RVNs expanded rights to dispense POM-V flea and worming treatments
consideration should be given to expanding the role of RVNs in the management of chronic cases, including repeat dispensing
consideration should be given to the potential role for RVNs in dispensing contraceptives, anthelmintics and vaccines in a zoo setting
it would be beneficial to incorporate the Suitably Qualified Person (SQP) role within RVN training
The BVA also recommends that there should be accessible, flexible and professionally recordable post-registration awards for RVNs from all academic backgrounds, and has reiterated its call for the protection of the title of 'Veterinary Nurse.'
BVNA Junior Vice President Jo Hinde RVN (pictured right) said: "BVNA strongly supports the vet-led approach as we believe working together as a team is the best way to improve both patient and staff welfare. We are delighted to be working on this project with BVA and are using our best efforts to continue to strive to strengthen the role of the RVN.
"We have always believed the VN title needs to be protected and this is increasingly important as the veterinary profession adapts to new challenges. It is vital that owners can be confident that their pet is being looked after by well-trained and RCVS-registered staff, as well as there being more clarity surrounding Schedule 3 procedures.
"The support for the advancement of the nursing role through post-registration qualifications is a welcome development and we believe this will help enable RVNs to follow their passion for a particular subject and allow them to significantly increase their knowledge in specific areas of interest. When following the vet-led model, this would result in a strong team of individuals with in-depth knowledge that can enhance their patients’ care."
Ceva Animal Health has renamed Tildren, its tiludronate-based bisphosphonate infusion for the treatment of bone spavin in horses, as Equidronate.
Tiludronate has been used to treat bone spavin and navicular disease in Europe for many years and was licensed for bone spavin in the UK in 2008. Ceva says trials published last year show that horses suffering lameness caused by bone spavin can show marked improvement following treatment with an Equidronate infusion, in combination with controlled exercise.
Bone spavin is a chronic aseptic osteoarthritis of the distal tarsal joints and is considered to be one of the most common forms of hindlimb lameness in the horse. Horses with bone spavin experience abnormal bone remodeling changes. According to the company, Equidronate helps to modulate the osteoclasts to help prevent excessive bone removal and give the osteoblasts a chance to catch up. This in combination with adjusting levels of exercise helps to harmonise the bone adaptation needed for the horse to perform its athletic duties.
In the trials one in four horses showed marked improvement; two in four showed improvement, which, when combined with other treatment, enabled the horse to resume former levels of activity and one in four horses showed no response.
Ceva Animal Health has produced a range of explanatory leaflets for horse owners on bone spavin, navicular disease and sacroiliac disease, as well as a helpful booklet detailing the discharge procedures for horses that have been treated with Equidronate.
For free copies and for further product information contact your Ceva sales representative, ring Ceva on 01494 781510 or visit the website at http://www.ceva.uk.com/
Whilst the decision has been welcomed by the BVA and leading animal charities, it has not been entirely free of controversy. According to various reports, the Press Association has seen a letter from Defra to the Royal Veterinary College in February this year, which said the scientific studies it had commissioned were 'not strong enough to support a ban'.
Talking to the BBC, Ian Gregory, a lobbyist for pet collar manufacturers said that charities had also exaggerated the shock delivered by the collars, which at typically one millijoule is 1000 times less than cattle fencing. He argued that: "The anecdotal problems reported with pet collars can be resolved by product standards rather than by banning a proven technology".
The government has stopped short of banning invisible fencing systems which can keep pets away from roads, saying that the devices are particularly useful for cat owners and animals often respond well to invisible fencing and quickly learn to stay within a boundary without receiving a static pulse.
BVA President John Fishwick said: "As we review the latest evidence on the welfare impact of pulse pet containment fences, we would like to see them covered by a code of practice, as well as the regulation of the sale of these devices and manufacturer’s instructions, to ensure that the potential adverse effects of use are highlighted to animal owners and consumers."
Photo: Shutterstock
Eprecis injection (eprinomectin) is an broad spectrum endectocide with activity against gastrointestinal nematodes in sheep1 and goats2.
After Eprecis injection Haemonchus contortus in the abomasum in goats were reduced by 97.8%2 and Trichostrongylus colubriformis in the small intestine were reduced by 98.7%2.
In lactating dairy ewes Eprecis injection was found to be 99% effective against gastrointestinal nematodes3 and was associated with an increased milk yield of 8%4.
The bioavailability of eprinomectin after one Eprecis injection in goats is larger than that reported for eprinomectin pour on5, 6, with Eprecis injection found to be four times more efficacious than eprinomectin pour-on across four dairy goat farms7.
In sheep, the efficacy of Eprecis injection against gastrointestinal nematodes in sheep is 99.6% versus 86.1% for a pour-on formulation8.
Eprecis injection is associated with higher plasma levels of eprinomectin and has a higher efficacy compared to eprinomectin pour-on in dairy ewes naturally infected with gastrointestinal nematodes8.
This is also achieved using five times less active than a pour-on formulation8.
Eprecis injection is administered subcutaneously and there is no need to part the fleece or coat along the animal’s back.
Ceva says it has excellent syringeability9 and a low dose volume (0.1ml/10kg) to help with accurate dosing of animals.
Harry Walby, ruminant veterinary advisor at Ceva Animal Health, said: “Eprecis injection is a highly effective broad-spectrum wormer that is now available in sheep and goats, as well as cattle.
"The injectable formulation not only allows accurate dosing, but there is no subclinical dose transfer between animals.”
Eprecis injection is available in 100ml and 250ml CLAS vials.
References
Merial Animal Health has launched Veloxa, a palatable broad spectrum dewormer for dogs, effective against roundworm, hookworm, whipworm and tapeworm.
Merial says Veloxa uses a proprietary technology which coats the bitter active ingredients in the beef-flavoured chewable tablets. In the company's palatability tests it achieved 97% acceptance.
Veloxa tablets are scored for accurate dosing and come in two sizes:
Christine Male, Product Manager of Veloxa said: "Merial has a strong heritage in anti-parasitics and understands how difficult it can be for pet owners to administer worming tablets, so we are extremely pleased to be able to offer Veloxa as part of the Merial anti-parasitics range."
The programme also introduces an extended nursing stream, focused on surgery and emergency and critical care nursing. In total, the conferences offer more than 27 hours of CPD each through the two veterinary streams, together with the two-day nursing stream.
VetsSouth takes place on 6-7 March, at Sandy Park in Exeter. VetsNorth takes place on 12-13 June at the AJ Bell Stadium in Manchester. Early-bird rates are now available for both events.
Speakers for 2019 include Ed Hall, Professor of Small Animal Internal Medicine at the University of Bristol, who will discuss pancreatitis in the dog; Dr Georgie Hollis, founder of Intelligent Wound Care, a company which aims to bring the best of modern wound care to veterinary practice and veterinary welfare campaigner and vet Emma Milne who will discuss welfare issues relating to brachycephalic animals.
An exhibition showcasing the latest veterinary products and services and featuring demonstrations and workshops from exhibitors will run alongside the conferences.
Matt Colvan, Event Director, said: "VetsSouth and VetsNorth have established themselves as friendly, relaxed conferences, offering high quality CPD for vets and vet nurses who may not be able to get easily to the larger veterinary events. We urge delegates to take advantage of our time-limited Early-bird offers and register without delay."
Elanco Companion Animal Health has launched a novel prescription flea treatment for dogs which, according to the company, combines a rapid kill rate with convenient monthly oral administration.
Elanco says Comfortis Chewable Tablets for Dogs start to kill fleas within 30 minutes, providing 100 per cent control in four hours, the fastest specific claim of any approved flea preventive.
The product is based on a unique active ingredient, Spinosad, a naturally occurring fermentation product of soil bacteria with a unique insecticidal effect. Since its launch in the United States in 2007, Comfortis has established itself as the number one recommended prescription flea medication in that country and has now received European authorisation.
Elanco says the combination of its rapid action and oral method of administration is expected to prove particularly helpful in cases including:
Jannes Nijland, marketing and innovation director for Elanco Companion Animal Health in Western Europe, said: "The veterinary profession has indicated a strong desire for a prescription only flea treatment. While vets remain the 'first port of call' for advice on flea medication, our research shows that only 42 per cent of dog owners still buy their treatments from practices. We believe that the launch of an alternative approach to flea control available from practices could help vets strengthen their client relationships."
He added: "Comfortis is the first product developed and launched by Elanco Companion Animal Health in Western Europe. It is a perfect demonstration of how we intend to deliver on our mission to help veterinarians help pets live longer, healthier and higher quality lives."
For further information about Comfortis, veterinary practices should contact their Elanco key account manager, or to contact the company directly on 01256 779881
Additional information about Elanco is available at www.elanco.com and the company can be contacted via email at elancoCAH.uk@lilly.com
The first, carried out by Nanna Luthersson and colleagues and published online in the Journal of Equine Veterinary Science in March, evaluated the laminitis risk factors in a group of Danish horses and ponies.1 It confirmed that Cold-blooded type animals <149cm, such as certain native ponies, as well as those being kept on high quality pasture were at an increased risk of developing laminitis for the first time. It also highlighted the important role that a change in grass intake, in terms of both type and amount, may play at any time of the year not only the spring as commonly thought.
The second study, funded in part by the PetPlan Charitable Trust, British Veterinary Association Animal Welfare Foundation Norman Hayward Fund and the Laminitis Trust, was undertaken in conjunction with Nicola Menzies-Gow (Royal Veterinary College) and published online in the Equine Veterinary Journal (EVJ) in August. The study evaluated the risk factors for the development of laminitis prior to the occurrence of the disease.2 It identified that low concentrations of the adipose tissue derived hormone adiponectin, together with high serum insulin concentrations (at rest and as part of a diagnostic test for PPID) may predict an increased risk of future pasture-associated laminitis.
It is hoped that future studies will be able to generate more robust cut off values, which will more accurately predict future laminitis development in an individual animal.
The RVC in collaboration with Waltham is now taking this forward through a study in which these markers are measured regularly, in conjunction with a detailed management assessment, in a group of ponies with no known history of laminitis at the start.
Clare Barfoot RNutr and the research and development manager at Spillers said: "The Danish study gives us important practical facts about the susceptibility of cold-blooded types, and is particularly applicable to natives in the UK. The second study gives hope that there may soon be a test or series of tests that will help predict those at an increased risk of suffering from pasture associated laminitis in the future thereby reducing the number of animals affected by this debilitating condition. In the meantime until we fully understand the condition it is sensible to manage all the risk factors we currently know about, in particular keeping your horse at a healthy weight."
Sarah Gasper, BEVA’S Learning Manager said: "Many of us on the BEVA education team understand exactly what it’s like to return to practice whether after a career break, paternity/maternity or sickness leave. We also understand the specific challenges of moving from mixed into equine practice.
"We have created these courses to help make the transition back to work as smooth as possible. We’ve tried to incorporate everything we wish we had had access to when we returned to practice!"
Reinvigorate your approach to equine practice will be held on 12th March 2019 at Lythe Hill Hotel, Haslemere. The lecture and forum based course will explore the latest advances in internal medicine, orthopaedics, and sports medicine, and how to apply them to develop evidence-based clinical approaches to common and emergency scenarios in practice.
Getting (back) into equine practice will be held on 13th March 2019 at Liphook Equine Hospital, Hampshire. This entirely practical day of CPD will all be about improving the confidence of established equine vets and for vets returning to work following a career break. The course will focus on the practical procedures that an established equine ambulatory vet might be expected to perform on a regular basis. In a new approach to CPD we are trialling a system where delegates can shape part of this unique CPD day for themselves, with an online poll pre-course to select from a choice of practicals.
Both courses will have childcare facilities to help support parents wishing to attend CPD.
BEVA will also be running a course on the fundamentals of sedation, field anaesthesia and castration on 27th and 28th March 2019 at World Horse Welfare, Snetterton, Norfolk. This 'hands-on' course is designed for new or recent graduates or those in mixed practice with varied levels of equine work. It comprises evening lectures on the first day to free up more time for hands-on training on day two. It will cover sedation and field anaesthesia required for common field surgery such as castration, both in theory and in a practical session, with the equine welfare charity venue able to provide a high number of colts for castration work. Nerve blocks and regional anaesthesia for other common procedures will also be covered on cadavers.
For further information on BEVA’s new CPD courses visit www.beva.org.uk/cpd
Andrea Tarr, Veterinary Prescriber’s founder and director said: "There is a lot of confusion about the various rules and regulations around medicine storage. This module makes sense of it all. It is an essential read for anyone who deals with veterinary medicines, particularly those preparing for a VMD or RCVS PSS medicines inspection."
Veterinary Prescriber’s reviews are presented as e-learning modules. All the modules are the result of a thorough literature search and collaboration between practising specialists, general practitioners and the publication's editorial team.
Veterinary Prescriber is supported by subscriptions which cost £9.95 per month (cancel anytime) for individuals or £25 per month (for a 12-month contract) for practices. The latter includes 12 months free access to https://cpd.veterinaryprescriber.org for your practice's vet nurses, vet receptionists and SQPs.
To subscribe visit: https://www.veterinaryprescriber.org/subscribe
For further information, contact: carlrussell@veterinaryprescriber.org telephone 07932 044904.
In current regional anaesthesia procedures two operators are often needed, with an assistant using 'feel' to inject the anaesthetic solution at the required pressure. This, says the company, means anaesthetic solutions can be injected at unsafe pressures. The new device incorporates a safety system that limits injection pressure, to reduce the risk of nerve injury.
Dr. Federico Corletto, Consultant Anaesthetist from Dick White Referrals said: “By turning regional anaesthesia into a one-person procedure, the technology also removes the challenges of communicating with an assistant regarding subjective injective pressure feel, thus removing the unpredictability of an untrained hand.”
Medovate says the use of ultrasound guided regional anaesthesia is becoming more common practice today, with the technique – which can help provide a higher level of visualisation for the practitioner – increasingly seen as a ‘gold standard’.
However, there are limitations and challenges that are not always present in the practice of adult human medicine. Nerve parathesia, for instance, is harder to ascertain in animals. Small animals such as cats also have increased sensitivity to local anaesthetics when compared with other species, necessitating much lower maximum doses be used.1
Brett Hughes, Homecare & Veterinary Business Manager at Vygon UK, said: "The device infuses at 0.5ml/second, and to vets the technology offers a valuable tool that can control injection small intervals at a time. This allows the veterinary practitioner to titrate appropriately to see the anaesthesia spread around a nerve bundle.
"There are a significant number of regional anaesthesia blocks completed in veterinary practice per annum globally, so potentially this NHS developed device could play a major role in the future of veterinary practice."
For more information, visit: https://www.medovate.co.uk/veterinary/safira-for-veterinary-applications and https://www.vygonvet.co.uk/
Reference
I invited Marc Abraham to come and answer some of the concerns raised on VetSurgeon about the ITV Pets Undercover programme.
His PR agency has instead pointed me in the direction of a response he has posted on his own website this morning. Click the link below.
http://www.marcthevet.com/response-to-%e2%80%98pets-undercover%e2%80%99/
Virbac has launched Marfloquin, a marbofloxacin-based antibiotic indicated for the treatment of multiple infectious diseases in cats and dogs.
Marfloquin is presented as a palatable, divisible tablet for once daily administration and is available in three tablet strengths:
Virbac Companion Animal Marketing Manager Simon Boulton MRCVS said: "Marbofloxacin is valued by practices for its efficacy in treating a wide range of skin, soft tissue, urinary tract and respiratory tract infections. The launch of Marfloquin gives them a cost-effective alternative and strengthens our existing antibiotic range, which includes Rilexine (cefalexin) and Enrox (enrofloxacin)."
For more information, contact your territory manager or call Virbac on 01359 243243
Instead of conducting major open surgery, Chris Shales, an RCVS and European Specialist in Small Animal Surgery, Andrew Kent, a European Specialist in Internal Medicine, and the cardiology team at Willows are using coil embolization, a minimally invasive technique which they say is far safer and less likely to lead to post-operative complications.
The procedure involves threading tiny coils, via the jugular vein, through the venous system and positioning them in the blood vessel that needs to be closed. The coils encourage the blood to form a clot and so, over time, seal the vein.
Chris said: "This procedure of treating intrahepatic portosystemic shunts is associated with a lower risk of mortality and a lower surgical morbidity rate when comparted to open surgery. The overall outcome of the two approaches is similar in terms of reduction of flow through the shunt vessel.
"Access is gained via a small incision in the neck to allow the team to operate on the liver via the jugular vein using fluoroscopy to visualise the placement of a stent within the vena cava and embolization coils within the abnormal vessel.
"Intrahepatic shunts can be extremely challenging for the surgical team to access with the result that standard, open surgical treatment of these abnormal vessels can risk life-threatening complications and animals can require a significant time to recover."
For more information about shunt surgery at Willows, contact Chris Shales or Small Animal Internal Medicine Specialist Andrew Kent on 0121 712 7070 or email enquiries@willows.uk.net.
Photo: Chris Shales, left, with Andrew Kent, centre, and cardiologist Mike Martin ('pass me a gin and tonic, would you').
The RCVS Disciplinary Committee has dismissed a case against Duncan Davidson MRCVS, a South London veterinary surgeon accused of clinical failings in relation to his treatment of a cat and of keeping poor and misleading clinical records.
The Committee heard the case against Dr Davidson, who was the sole practitioner and owner of Mitcham Veterinary Clinic until his retirement from clinical practice in November 2014, at a hearing which concluded on 22nd January.
The first charge against Dr Davidson alleged that, between 7 November 2013 and 13 December 2013, he had failed to provide adequate care to Ameira, an Egyptian Mau cat. The charge was in four parts: that he had inappropriately administered corticosteroids; had failed to administer adequate fluid therapy; discharged the cat to its owner suggesting a referral when he should have suggested or arranged a same-day referral; and that he failed to communicate the urgency of referral/ further investigation of the cat’s condition to her owner.
The second charge was that, between 7 November 2013 and 17 January 2014, he dishonestly made retrospective alterations to Ameira’s clinical records and failed to keep clear, accurate and detailed clinical records.
From the outset Dr Davidson, who attended the hearing, did not admit the charges against him and denied that his conduct, if found proven, constituted serious professional misconduct.
A summary of the circumstances of the case were that the cat had been admitted to Dr Davidson’s practice on 8 November 2013 with poor appetite and a piece of thread in its mouth. The cat was later admitted, on 21 November, with dehydration and was diagnosed with a linear foreign body (ie the thread) on 25 November 2013. Dr Davidson continued to treat Ameira with corticosteroids and rehydration fluids at the practice but a second opinion was sought by Ameira’s owner from a nearby veterinary practice. This practice referred the cat to the Royal Veterinary College for treatment. Surgery to remove the linear foreign body was undertaken on 13 December 2013, albeit with a poor prognosis, and Ameira subsequently suffered two cardiac arrests and died on 14 December 2013.
In terms of its findings on the first charge, the Committee heard from an expert witness, Mr Hurst, regarding the use of the corticosteroids which were administered to the cat by Dr Davidson on 22, 27 and 30 November 2013 and 5 and 12 December 2013. Although Mr Hurst said that a minority of veterinary surgeons may have provided corticosteroids when the cat was first presented to Dr Davidson on 8 November; when it was determined by Dr Davidson’s colleague Mr Holden that the cat’s condition was due to it having ingested thread, the use of corticosteroids was inappropriate from then on and would be considered contra-indicated. The Committee found this charge proven.
The Committee did not find the charge against Dr Davidson that he failed to provide adequate fluid therapy proven. When the cat was presented to the practice on 21 November 2013 suffering from dehydration, fluid rehydration was given but not administered intravenously. The Committee concluded that intravenous hydration was not necessary because the clinical records from both Dr Davidson and the Royal Veterinary College indicated that Ameira was only moderately dehydrated.
Regarding the referral of Ameira, the Committee could not be sure that the cat was sufficiently unwell on 23 November that it required immediate referral. Dr Davidson had sent Ameira home with her owner on that date on the basis that she was stable and that he would arrange a referral for her on 25 November. There was conflicting evidence from Dr Davidson and Ameira’s owner on the matter of whether, on 23 November, Ameira’s owner was advised that the cat’s condition was critical or that a referral was urgently required. Dr Davidson accepted that he did not seek to make an urgent referral. The charge was not proven.
Regarding the communication of the urgency for further investigation of Ameira’s condition, the Committee found that there was insufficient evidence to suggest that Dr Davidson did not adequately communicate with Ameira’s owner after the diagnosis of a linear foreign body was made on 25 November. According to Dr Davidson, he explained the risk of further damage to the oesophageal and gastrointestinal tract and offered further radiography. This was strongly contested by Ameira’s owner. However, ultimately the Committee were unable to be satisfied as to which version was correct to the necessary standard of proof required.
Regarding the retrospective amendment of clinical records, the Committee found that although there were some “troubling aspects” about the case, particularly evidence of a telephone call with the RCVS Professional Conduct Department in which Dr Davidson said that no retrospective alterations had been made, it was unable to be satisfied so as to be sure of his motivation for changing the records. His contention was that changes had been made as he was concerned he would be subject to civil litigation by Ameira’s owner. However, the Committee found the charge not proven, also taking into account Dr Davidson’s good character and unblemished professional record over 40 years.
However, the Committee did find that Dr Davidson’s clinical records were illegible. Dr Davidson recognised the poor quality of his handwriting, which the veterinary surgeons to whom Ameira was referred were unable to understand. The Committee found this charge proven.
Taking into account the charges it found proven, the Committee then considered whether they constituted serious professional conduct either individually or cumulatively. Judith Webb, who chaired the Committee and spoke on its behalf, said: "It does not consider that on the facts of this case the administration of corticosteroids amounted to disgraceful misconduct."
She added: "The Committee has already emphasised the importance of making legible handwritten records but it does not consider that the failure to do so in this case amounts to disgraceful misconduct.... The Committee has found that Dr Davidson was wrong to make retrospective entries in this case without making it clear when such alterations were made. The Committee does not consider that in this case the making of those alterations was capable of being disgraceful misconduct. The case is dismissed."
The survey polled 671 veterinary surgeons in May and June 2017.
92% of those who are now in non-clinical roles had worked in clinical practice in the past. 73% had previously worked in mixed practice, 49% in companion animal practice, 33% in production animal practice and 8% in equine practice.
32% are now in academia, whilst 21% have moved to work in commerce and industry.
Mostly, veterinary surgeons gave positive reasons for moving to non-clinical work: 43% said they were looking for a new challenge and 33% said they were looking for a different type of work.
Others were looking to improve their work-life balance: 24% said they wanted a role with no out-of-hours work, 14% said they wanted more flexible working hours and 10% said clinical work was incompatible with family or outside commitments.
21% cited difficulty in progressing with their clinical career as a reason for moving whilst 19% said they were looking for less stress at work.
There were some differences between men and women in the timing of their career change and the reasons behind it. Women tended to leave clinical practice earlier in their career; an average of 6.5 years after they qualified compared to 8 years for men.
Reasons related to working hours and flexibility were more prominent motivations for women to move from clinical practice (54% of female vets compared to 31% of male vets). On the other hand, male vets were more likely than female vets to cite reasons related to a desire to do a different type of work (44% of male vets compared to 24% of female vets).
BVA Senior Vice President, Gudrun Ravetz said: "These figures show that there is a sizeable percentage of practising vets who are making the move into non-clinical roles and that there are a variety of reasons behind their decision. There is a huge diversity of career paths open to vets and it’s important both for those who are already in practice and for those considering a veterinary career to be aware of all the options available.
"I have had a portfolio career myself that involved clinical practice in all different business models including charity practice and industry and I know that the most important thing is for vets to feel fulfilled in their chosen roles and understand that there is a wide range of opportunity available to them.
"However, we also know that practices are seriously worried about being able to recruit and retain staff. Looking at the reasons for leaving – including a desire for more flexibility, a better work/life balance, and concerns about stress – this has to be a wake-up call to all employers to think about whether we can do things differently to support our colleagues.
"BVA has a role to play too and many of the Vet Futures actions are designed to address these issues, including the workforce study commissioned by BVA, the development of a careers hub, and our support for the Mind Matters Initiative led by RCVS, amongst others. These are issues that the profession must tackle together."